肥胖是心血管疾病最強的推手之一。但讓體重長期、有效地下降，光靠藥物真的足夠嗎？ 兩項最新發表於頂尖醫學期刊的大型研究，給了我們清楚的答案。
Obesity is one of the strongest drivers of cardiovascular disease. But is medication alone enough for durable, meaningful weight loss? Two major studies recently published in top medical journals give us a clear answer.
過多的脂肪——尤其是堆積在腹腔與器官周圍的「內臟脂肪」——會不斷釋放促發炎物質，造成慢性低度發炎。這個持續的炎症環境，正是推動以下心血管問題的幕後黑手：
Excess fat — especially visceral fat packed around abdominal organs — continuously releases pro-inflammatory substances, creating a state of chronic low-grade inflammation. This persistent inflammatory environment is the key driver behind the following cardiovascular problems:
肥胖患者血管阻力增加、腎素-血管收縮素系統亢進，使血壓持續偏高，大幅增加中風與心臟衰竭風險。
Obesity increases vascular resistance and activates the renin-angiotensin system, keeping blood pressure chronically elevated and raising the risk of stroke and heart failure.
三酸甘油酯升高、高密度脂蛋白（好的膽固醇）下降，加速動脈粥狀硬化，是冠心病的重要推手。
Elevated triglycerides and reduced HDL cholesterol accelerate atherosclerosis, significantly contributing to coronary artery disease.
長期高血糖、高血壓、高血脂三重打擊，讓供應心肌的冠狀動脈逐漸狹窄，最終可能導致心肌梗塞。
The triple threat of chronic hyperglycemia, hypertension, and dyslipidemia progressively narrows coronary arteries, potentially leading to myocardial infarction.
反覆性夜間低血氧，直接對心臟造成壓力，是心律不整與心臟衰竭的獨立危險因子。
Repetitive nocturnal hypoxia directly stresses the heart and is an independent risk factor for arrhythmia and heart failure.
關鍵問題：要從根本降低心血管風險，需要的不只是「讓血壓數字好看」或「壓低血脂指數」，而是讓那個製造麻煩的源頭——過多的脂肪——真正被長期有效地移除。
The key question: Truly reducing cardiovascular risk requires more than making blood pressure or lipid numbers look acceptable. It requires sustainably eliminating the root cause — excess fat — over the long term.
2025年發表於 JAMA Surgery 的大型研究，以超過三萬名肥胖患者的真實世界資料，直接比較了代謝手術與 GLP-1 受體促效劑（包括司美格魯肽、替西帕肽）在體重下降、共病改善與醫療費用上的差異。
A 2025 large-scale study published in JAMA Surgery used real-world data from over 30,000 obese patients to directly compare metabolic bariatric surgery (MBS) with GLP-1 receptor agonists (including semaglutide and tirzepatide) in weight loss, comorbidity improvement, and healthcare costs.
| 指標Outcome | GLP-1 藥物組GLP-1 RA | 代謝手術組Bariatric Surgery |
|---|---|---|
| 平均總體重下降Mean total weight loss | 10.3% | 28.3% |
| 達到持續 5% 體重下降Achieved sustained 5% weight loss | 71.6% | 98.8% |
| 達到持續 10% 體重下降Achieved sustained 10% weight loss | 45.9% | 96.0% |
| 兩年總醫療費用（美元）Total 2-year costs (USD) | $63,483 | $51,794 |
重要提示：GLP-1 藥物是「長期服藥才有效」的治療——停藥後體重幾乎必然反彈，心血管保護效果也隨之消退。相較之下，代謝手術的減重效果在長期追蹤中仍能維持，且兩年總費用反而比持續用藥更低約 NT$ 36 萬（約美金 11,689 元）。
Important note: GLP-1 drugs only work as long as they're taken — weight typically rebounds after discontinuation, and cardiovascular protection fades with it. By contrast, the weight loss from bariatric surgery is sustained long-term, and total two-year costs are approximately $11,689 USD lower than continuous medication.
追蹤期結束時，手術組患者在以下所有心血管風險因子上，盛行率均顯著低於 GLP-1 藥物組：
At the end of follow-up, patients in the surgery group had significantly lower rates of all the following cardiovascular risk factors compared to the GLP-1 RA group:
手術組：60.7% vs 藥物組：74.5%
手術後高血壓盛行率顯著降低，減少了對長期降血壓藥物的依賴。
Surgery: 60.7% vs GLP-1 RA: 74.5%
Significant reduction in hypertension prevalence, decreasing reliance on antihypertensive medication.
高血脂：手術組 49.2% vs 藥物組 69.9%
高膽固醇：手術組 11.4% vs 藥物組 20.3%
動脈粥狀硬化的關鍵推手，術後大幅改善。
Hyperlipidemia: Surgery 49.2% vs GLP-1 RA 69.9%
Hypercholesterolemia: Surgery 11.4% vs GLP-1 RA 20.3%
Key drivers of atherosclerosis, substantially improved after surgery.
手術組：11.0% vs 藥物組：15.9%
周邊動脈疾病：手術組 4.9% vs 藥物組 7.9%
代謝手術在保護大血管方面，效果尤為突出。
Surgery: 11.0% vs GLP-1 RA: 15.9%
Peripheral artery disease: Surgery 4.9% vs GLP-1 RA 7.9%
Bariatric surgery offers particularly notable protection for large blood vessels.
手術組：34.6% vs 藥物組：49.4%
夜間缺氧對心臟的傷害減輕，有助於降低心律不整與心血管事件的風險。
Surgery: 34.6% vs GLP-1 RA: 49.4%
Reduced nocturnal hypoxia helps lower the risk of arrhythmia and cardiovascular events.
2026年發表於 JAMA Network Open 的研究，追蹤了 3,066 名患者兩年的體組成變化——不只看體重，而是深入分析「減掉了什麼」。結果顯示，代謝手術在改善心血管最關鍵的體組成比例上，表現遠優於 GLP-1 藥物。
A 2026 study in JAMA Network Open tracked body composition changes in 3,066 patients over two years — looking beyond the scale to analyze what was actually being lost. Surgery outperformed GLP-1 medications in improving the body composition ratio most critical for cardiovascular health.
為什麼肌肉：脂肪比很重要？研究顯示，脂肪比例越高，心血管死亡風險越高；肌肉比例越高，預後越好。單純用 BMI 或體重來評估肥胖治療效果是不夠的——真正的健康改善，需要同時減少脂肪、相對保留肌肉，讓身體組成往更有益的方向移動。代謝手術在這個層面的表現，目前仍優於藥物治療。
Why does the muscle-to-fat ratio matter? Research shows that higher fat mass is associated with higher cardiovascular mortality, while higher fat-free mass predicts better outcomes. BMI alone is insufficient for evaluating obesity treatment — true health improvement requires reducing fat while relatively preserving muscle. Bariatric surgery currently leads medications on this dimension.
與 GLP-1 藥物組相比，代謝手術組在追蹤期間的醫療資源使用，全面性地更低：
Compared to the GLP-1 RA group, the surgery group used substantially fewer healthcare resources across all measures during follow-up:
這些數字告訴我們：代謝手術對心血管的保護，不只是反映在數字上——它真實地減少了患者因心血管或相關疾病需要緊急就醫的次數。手術的「初始投資」，換來的是長期更低的醫療負擔。
These numbers tell us that bariatric surgery's cardiovascular protection isn't just seen in statistics — it genuinely reduces the number of times patients need emergency or acute care for cardiovascular and related conditions. The "upfront investment" of surgery yields substantially lower long-term healthcare costs.
2025 年發表於 Annals of Surgery 的頭對頭真實世界研究（n=812），追蹤了代謝手術與 GLP-1 藥物治療一年後的心血管動脈粥樣硬化風險變化。結果出乎意料地發人深省：
A 2025 head-to-head real-world study published in Annals of Surgery (n=812) tracked changes in atherosclerotic cardiovascular disease (ASCVD) risk after one year of bariatric surgery versus GLP-1 therapy. The results were striking:
為什麼短期相近，長期卻差這麼多？GLP-1 藥物的效果高度依賴持續用藥。停藥後，體重幾乎必然反彈，心血管保護隨之消退。代謝手術透過永久改變胃腸道解剖結構，讓體重長期維持在較低水平，心血管風險的改善也因此更加持久。終生風險才是我們真正在意的數字。
Why do short-term results look similar but lifetime outcomes diverge so dramatically? GLP-1 drugs depend entirely on continuous use. After stopping, weight almost always rebounds and cardiovascular protection fades with it. Bariatric surgery permanently alters gastrointestinal anatomy, sustaining lower body weight long-term — and with it, lasting cardiovascular risk reduction. Lifetime risk is the number that truly matters.
• BMI ≥ 37.5，或
• BMI ≥ 32.5 合併高血壓、糖尿病、睡眠呼吸中止症等
• 年紀較輕（30–55歲），在嚴重心血管事件發生前進行手術，保護效果更顯著
• BMI ≥ 37.5, or
• BMI ≥ 32.5 with hypertension, diabetes, sleep apnea, etc.
• Younger patients (30–55 years): surgery before serious CVD events yields the greatest long-term protection
心血管疾病是「時間積累」的結果——每多一年處於肥胖、高血壓、高血脂的環境，動脈就多承受一年損傷。等到心肌梗塞發生才處理，代價往往遠高於提早介入。
Cardiovascular disease is the product of cumulative time — every additional year of obesity, hypertension, and dyslipidemia adds another year of arterial damage. Waiting until a heart attack occurs carries a far higher cost than early intervention.
是的。最新大型真實世界研究（Barrett et al., JAMA Surgery 2025，逾三萬患者）顯示，接受代謝手術後，高血壓、高血脂、冠狀動脈疾病、周邊動脈疾病及睡眠呼吸中止症的盛行率，均顯著低於持續使用 GLP-1 藥物的患者。體重長期下降超過 20%，讓這些心血管風險因子得以從根本改善。
Yes. A major real-world study (Barrett et al., JAMA Surgery 2025, over 30,000 patients) found that after bariatric surgery, rates of hypertension, dyslipidemia, coronary artery disease, peripheral artery disease, and sleep apnea were all significantly lower than in patients continuously treated with GLP-1 receptor agonists. Sustained long-term weight loss exceeding 20% allows these cardiovascular risk factors to improve at their root.
兩者都有心血管保護效果，但在頭對頭的直接比較中，手術在長期體重下降（28.3% vs 10.3%）及所有心血管風險因子的改善上，均優於 GLP-1 藥物。最重要的差別是：GLP-1 藥物的效果依賴於持續服藥，停藥後體重幾乎必然反彈，心臟保護效果也隨之消退；手術的效果則較為持久。
Both offer cardiovascular protection, but in head-to-head comparison, surgery outperforms GLP-1 drugs in long-term weight loss (28.3% vs 10.3%) and improvement across all cardiovascular risk factors. The most important difference: GLP-1 drug effects depend on continuous use — weight typically rebounds after stopping, taking the heart protection with it. Surgery's effects are more durable.
任何減重方式都會有一定程度的肌肉流失，手術也不例外。但根據 Wang et al. (JAMA Network Open 2026) 的研究，手術後雖有約 11.7% 的肌肉量減少，但脂肪量同時減少了近 50%，讓肌肉：脂肪比例（FFM:FM ratio）從 1.0 改善至 2.0——這是更健康的體組成。重要的是，搭配適當的術後飲食（足夠蛋白質）與規律運動，可以有效減少肌肉流失、優化體組成。
All weight loss approaches involve some muscle loss — surgery is no exception. However, according to Wang et al. (JAMA Network Open 2026), while surgery produces approximately 11.7% muscle mass reduction, fat mass simultaneously decreases by nearly 50%, improving the FFM-to-FM ratio from 1.0 to 2.0 — a healthier body composition. Importantly, adequate post-operative protein intake and regular exercise can effectively minimize muscle loss and optimize body composition.
符合健保條件者（BMI ≥ 37.5，或 BMI ≥ 32.5 合併高危共病）受益最為顯著。年紀越輕、在嚴重心血管事件發生前接受手術，越能從根本上改變心血管風險的軌跡。如果你正在用多種藥物控制血壓、血脂、血糖，卻發現體重遲遲無法有效下降，手術可能是更根本的解方。
Patients meeting NHI criteria (BMI ≥ 37.5, or BMI ≥ 32.5 with high-risk comorbidities) benefit most significantly. The younger the patient — and the earlier surgery occurs before serious cardiovascular events develop — the more surgery can fundamentally alter the cardiovascular risk trajectory. If you're managing blood pressure, lipids, and blood sugar with multiple medications but weight remains stubbornly resistant, surgery may offer a more fundamental solution.
我們的評估不只看體重與 BMI，更重視心臟、代謝與整體健康狀態，為你量身規劃最適合的治療路徑。
Our evaluation goes beyond weight and BMI — we assess cardiac, metabolic, and overall health to design the most appropriate personalized treatment plan for you.
1. Barrett TS, Hafermann JO, Richards S, LeJeune K, Eid GM. Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists. JAMA Surg. 2025;160(11):1232-1239. doi:10.1001/jamasurg.2025.3590
2. Wang Z, Wang L, Zhang X, et al. Body Composition Changes After Bariatric Surgery or Treatment With GLP-1 Receptor Agonists. JAMA Netw Open. 2026;9(1):e2553323. doi:10.1001/jamanetworkopen.2025.53323
3. Ghusn W, et al. Metabolic and Bariatric Surgery vs Glucagon-like Peptide-1 Receptor Agonist Therapy: A Head-to-Head Comparison in Improvement of Cardiometabolic Risk Profiles. Ann Surg. 2025. doi:10.1097/SLA.0000000000007064. PMID: 42002851